P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

A. Rubinstein; T. Bridges; D. McNeil; R. Tachdjian; H. Wedner; R. Wasserman; H. Leibl; C. Rabbat; R. Honigberg; L. Yel

首页> 外文期刊>Annals of allergy, asthma, and immunology >P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

【24h】

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

机译：P279透明质酸酶促进皮下免疫球蛋白的授权后安全性研究初级免疫缺陷患者患者治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Annals of allergy, asthma, and immunology》 |2017年第5期|共1页
作者
A. Rubinstein; T. Bridges; D. McNeil; R. Tachdjian; H. Wedner; R. Wasserman; H. Leibl; C. Rabbat; R. Honigberg; L. Yel;
展开▼
作者单位

Bronx NY;

Albany GA;

Columbus OH;

Santa Monica CA;

St. Louis MO;

Dallas TX;

Vienna Austria;

Chicago IL;

Chicago IL;

Cambridge MA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases [J] . A. Rubinstein, T. Bridges, D. McNeil, Annals of allergy, asthma, and immunology . 2017,第5期

机译：P279透明质酸酶促进皮下免疫球蛋白的授权后安全性研究初级免疫缺陷患者患者治疗
2. POST-AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES [J] . Rubinstein A., Bridges T., McNeil D., Annals of allergy, asthma, and immunology . 2017,第5Suppla1期

机译：透明化酶促进皮下免疫球蛋白10％治疗原发性免疫缺陷疾病治疗的后授权安全性研究
3. Interim Analysis of the Global Post Authorization Safety Study of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Treatment in Patients With Primary Immunodeficiency Diseases [J] . Rubinstein Arye, Bridges Tracy, McNeil Donald, Journal of Clinical Immunology . 2018,第3期

机译：透析酶促进皮下免疫球蛋白10％治疗初级免疫缺陷患者的临时分析
4. Safety Profile of subcutaneously Immunoglobulin G (SUBCUVIA) treatment in Children <= 12 Years with primary Immunodeficiencies [C] . Permin H., Herlin T., Gajek H., European Congress of Immunology . 2009

机译：皮下免疫球蛋白G（Subcuvia）治疗儿童的安全性<= 12年，主要免疫缺失
5. A longitudinal study of fetal tissue transplantation surgery for the treatment of Parkinson's disease: Can quality of life and optimism at baseline predict patient outcome 10 years later? [D] . Fazio, Emily B. 2011

机译：胎儿组织移植手术治疗帕金森氏病的纵向研究：基线时的生活质量和乐观情绪能否预测10年后的患者预后？
6. Long-Term Tolerability Safety and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency [O] . Richard L. Wasserman, Isaac Melamed, Mark R. Stein, -1

机译：重组人透明质酸酶促进皮下输注人免疫球蛋白对原发性免疫缺陷的长期耐受性安全性和功效
7. Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies [O] . Mark R. Stein, Richard L. Wasserman, Isaac Melamed, 2016

机译：在Ighy相3研究中，用重组人透明质酸酯酶促进免疫球蛋白G（Ighy）治疗的重组人透明化酶G（Ighy）治疗的局部不良反应率随着时间的推移而降低

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

著录项

引文网络

相似文献

相关主题

期刊订阅